0001209191-22-023284.txt : 20220405 0001209191-22-023284.hdr.sgml : 20220405 20220405182030 ACCESSION NUMBER: 0001209191-22-023284 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220401 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RASTETTER WILLIAM H CENTRAL INDEX KEY: 0001205903 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 22808666 MAIL ADDRESS: STREET 1: 9885 TOWNE CENTRE DR. CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-01 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001205903 RASTETTER WILLIAM H 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 0 0 0 Common Stock 2022-04-01 4 M 0 20000 6.66 A 44750 D Common Stock 2022-04-01 4 S 0 10728 94.926 D 34022 D Non-Qualified Stock Option 6.66 2022-04-01 4 M 0 20000 6.66 D 2022-05-23 Common Stock 20000 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $93.48 to $95.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted May 23, 2012 and vested in 12 equal monthly installments beginning June 23, 2012. /s/ Darin Lippoldt, Attorney-in-Fact 2022-04-05